11/18
01:18 pm
moln
Molecular Partners (NASDAQ:MOLN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Molecular Partners (NASDAQ:MOLN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
01:30 am
moln
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action [Yahoo! Finance]
Medium
Report
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action [Yahoo! Finance]
11/12
01:00 am
moln
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
Medium
Report
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
11/7
01:14 am
moln
Molecular Partners (NASDAQ:MOLN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Molecular Partners (NASDAQ:MOLN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/3
01:00 am
moln
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
High
Report
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
11/3
01:00 am
moln
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
High
Report
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
10/30
04:00 pm
moln
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
Medium
Report
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
9/30
02:09 am
moln
Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company [Yahoo! Finance]
Medium
Report
Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company [Yahoo! Finance]